A retrospective multicenter cohort study assessing the weight gain after Antiretroviral Therapy initiation in ART naïve patients with HIV
Latest Information Update: 07 Sep 2023
At a glance
- Drugs Abacavir (Primary) ; Abacavir/dolutegravir/lamivudine (Primary) ; Atazanavir/ritonavir (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Cobicistat/darunavir/emtricitabine/tenofovir alafenamide (Primary) ; Darunavir (Primary) ; Darunavir/ritonavir (Primary) ; Dolutegravir (Primary) ; Dolutegravir/emtricitabine/tenofovir-alafenamide (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Integrase inhibitors (Primary) ; Rilpivirine (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 13 Nov 2020 New trial record
- 28 Oct 2020 Results published in the JAIDS